Phase 4
Completed N=70
Nebulized Hypertonic Saline for Inpatient Use in COPD
Source: ClinicalTrials.gov NCT02266875 ↗Enrolled (actual)
70
Serious AEs
0.0%
Results posted
Nov 2017
Primary outcomePrimary: Change in Patient-Reported Breathing Difficulty - Using Modified Borg Dyspnea Scale — -1.4; -1.0 units on a scale — p=0.320
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
A comparison of albuterol treatments using hypertonic saline (3%) versus standard saline (0.9%) in patients with admitted patients COPD in regard to Modified Borg Dyspnea scale scores after 4 treatments within 24 hours.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Patient-Reported Breathing Difficulty - Using Modified Borg Dyspnea Scale |
-1.4; -1.0 | 0.320 |
| SECONDARY 30 Day Readmission |
3; 3 | >0.999 |
| SECONDARY 30 Day All Cause Mortality |
0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Patients at least 18 years of age
- Admitted to Doctors Hospital with a clinical diagnosis of COPD
- Documented obstruction on spirometry from prior records available at the time of the study.
Exclusion Criteria
- Patients younger than 18 years of age
- Spirometry data not available
- History of smoking less than twenty pack-years
- Possibility of other primary cause of the patient's change in dyspnea or cough (e.g. pneumonia, congestive heart failure with pulmonary edema, myocardial infarction)
- Patient is found to have a different primary cause after initial enrollment
- Non-English speaking subjects
Data sourced from ClinicalTrials.gov (NCT02266875). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.